Since that time, the vast majority of therapeutic developments have been directed towards the inhibition of amyloid-β (Aβ) and tau formation, and have been unsuccessful at reversing cognitive decline in AD patients despite reductions in pathological biomarkers [6,7]. The gene discussed is MAPT; the disease is Alzheimer disease.